BCTX Stock Summary and Trading Ideas (Briacell Therapeutics Corp. - Common Shares | NASDAQ:BCTX)

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Briacell Therapeutics Corp. - Common Shares trades on the NASDAQ stock market under the symbol BCTX.

As of January 29, 2026, BCTX stock price declined to $4.31 with 340,022 million shares trading.

BCTX has a beta of 1.18, meaning it tends to be more sensitive to market movements. BCTX has a correlation of 0.02 to the broad based SPY ETF.

BCTX has a market cap of $26.77 million. This is considered a Sub-Micro Cap stock.

Last quarter Briacell Therapeutics Corp. - Common Shares reported $0 in Revenue and -$4.35 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$1.07.

In the last 3 years, BCTX traded as high as $1,214.99 and as low as $4.10.

BCTX has underperformed the market in the last year with a price return of -92.7% while the SPY ETF gained +16.5%. BCTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -65.4% and -4.0%, respectively, while the SPY returned +1.3% and +0.3%, respectively.

BCTX support price is $4.23 and resistance is $5.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTX shares will trade within this expected range on the day.